Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: An Italian validation study

Annals of Oncology

Volumn 23, Issue 7, 2012, Pages 1832-1837

  Granata, R ^a   Miceli, R ^a   Orlandi, E ^a   Perrone, F ^a   Cortelazzi, B ^a   Franceschini, M ^a   Locati, L D ^a   Bossi, P ^a   Bergamini, C ^a   Mirabile, A ^a   Mariani, L ^a   Olmi, P ^a   Scaramellini, G ^a   Potepan, P ^a   Quattrone, P ^a   Ang, K K ^b   Licitra, L ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Human papillomavirus status; Oropharyngeal cancer smoking

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; PROTEIN P16;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL DECISION MAKING; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OROPHARYNX CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SMOKING HABIT; SURVIVAL RATE; VALIDATION PROCESS; WART VIRUS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; GENES, P16; HUMANS; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; SMOKING;

EID: 84864316654     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr544     Document Type: Article

References (28)

1. Seiwert TY, Salama JK, Vokes EE. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol 2007; 4: 156-171.
2. Jeremic B, Shibamoto Y, Milicic B et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000; 18: 1458-1464.
3. Adelstein DJ, Li Y, Adams GL et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21: 92-98.
4. Paccagnella A, Orlando A, Marchiori C et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994; 86: 265-272.
5. Domenge C, Hill C, Lefebvre JL et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d' Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer 2000; 83: 1594-1598.
6. Pignon JP, le Maitre A, Maillard E et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an updated of 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4-14.
7. Forastiere AA, Shank D, Neuberg D et al. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA 390). Cancer 1998; 82: 2270-2274.
8. Hitt R, López-Pousa A, Martínez-Trufero J et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005; 23: 8636-8645.
9. Vermorken JB, Remenar E, van Herpen C et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695-1704.
10. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705-1715.
11. Blanchard P, Bourredjem A, Bourhis J et al. Taxane-cisplatin-5-FU as induction chemotherapy in locally advanced head and neck squamous cell carcinoma: an individual patient data meta-analysis of the MACH-NC Group. Radiother Oncol 2011; 98Suppl 1S6
12. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (The " DEALE" ). I. Validation of the method. Am J Med 1982; 73: 883-888.
13. Gómez-Batiste X, Tuca A, Corrales E et al. Resource consumption and costs of palliative care services in Spain: a multicenter prospective study. J Pain Symptom Manage 2006; 31: 522-532.
14. Ferguson MK. Optimal management when unsuspected N2 nodal disease is identified during thoracotomy for lung cancer: cost-effectiveness analysis. J Thorac Cardiovasc Surg 2003; 126: 1935-1942.
15. Hayashi K, Abe K, Yano F et al. Should mediastinoscopy actually be incorporated into the FDG PET strategy for patients with non-small cell lung carcinoma?. Ann Nucl Med 2005; 19: 393-398.
16. Lievens Y, Kesteloot K, Van den Bogaert W CHART in lung cancer: economic evaluation and incentives for implementation. Radiother Oncol 2005; 75: 171-178.
17. Hollenbeak CS, Lowe VJ, Stack BC, Jr The cost-effectiveness of fluorodeoxyglucose 18-F positron emission tomography in the N0 neck. Cancer 2001; 92: 2341-2348.
18. Brown RE, Hutton J, Burrell A Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics 2001; 19: 1091-1102.
19. Launois R, Reboul-Marty J, Henry B et al. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics 1996; 10: 504-521.
20. Martin SC, Gagnon DD, Zhang L et al. Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer. Pharmacoeconomics 2003; 21: 1153-1169.
21. Dietl B, Marienhagen J, Schaefer C et al. [Survival with distant metastatic disease in head and neck cancer. A retrospective analysis]. HNO 2007; 55: 785-786. 788-791
22. Guntinas-Lichius O, Rühlow S, Veelken F et al. Quality of life during first-line palliative chemotherapy for recurrent and metastatic head and neck cancer with weekly cisplatin and docetaxel. J Cancer Res Clin Oncol 2009; 135: 901-908.
23. National Institute for Health and Clinical Excellence (NICE)Guide to the Methods of Technology Appraisal 2008http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf (7 November 2011, date last accessed)
24. Vermorken JB. A new look at induction chemotherapy in locally advanced head and neck cancer. Oncologist 2010; 15Suppl 31-2.
25. Parthan A, Posner MR, Brammer C et al. Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck. Head Neck 2009; 31: 1255-1262.
26. Smith DH, Adams JR, Johnston SR et al. A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK. Ann Oncol 2002; 13: 1590-1597.
27. Capri S, Cattaneo G Cost-minimization analysis of pegylated liposomal doxorubicin versus topotecan for the treatment of ovarian cancer in Italy. Clin Ther 2003; 25: 1826-1845.
28. Ojeda B, de Sande LM, Casado A et al. Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain. Br J Cancer 2003; 89: 1002-1007.